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Abstract
Background: Antagonistic analogues of GnRH for the treatment of prostate cancer may be used
clinically in persons for whom return to fertility after such treatment is important or desirable. The
purpose of this study was, therefore, to evaluate the effects of a long term treatment with orntide,
a GnRH antagonist, on testosterone levels and fertility in male rats.
Methods: Two groups of male rats received either 120-day orntide microspheres (8.8 mg orntide/
kg/120 days) or vehicle alone (control group). Serum orntide and testosterone levels in both
groups were monitored at certain intervals for 9 months from the initiation of treatment. After
recovery of normal serum testosterone levels in the treated animals, each rat was housed with two
proven breeder, but drug-naive, females.
Results: All mates of treated rats achieved pregnancy as rapidly as the mates of control rats
although two of the control rats did not sire a litter with either female and one sired only one litter.
The mean size of the litters of treated (12.3 offspring per litter) and control (10.6 offspring per
litter) were similar. All offspring were grossly normal morphologically and behaviorally during the
time to weaning.
Conclusions: These results suggest that lack of fertility due to testosterone suppression is
reversible after cessation of treatment with this GnRH antagonist.
Background
Analogues of gonadotrophin releasing hormone (GnRH)
are being used for a variety of hormone-dependent hu-
man disease states. Prominent among these are prostate
cancers and endometriosis [1–5]. One class of these ana-
logues, GnRH superagonists, such as leuprorelin, trip-
torelin, goserelin, and buserelin, have been in use for
some years. They act by hyper-stimulation of GnRH re-
ceptors on the gonadotroph cells of the pituitary, result-
ing in an initial phase of elevated levels of testosterone
and androgens, followed by down-regulation of the re-
ceptors. This eventually results in blocking release of LH
and FSH and secondarily preventing synthesis/release of
testosterone or estrogen from the gonads. The superag-
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Figure 1
Structure of orntide acetate (A) and amino acid sequences for GnRH (B) and leuprolide (C)
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onists have a long safety record and are successfully used
clinically in persons, who later have children. In this
class of GnRH analogues which are commercially availa-
ble, return to fertility does not appear to be a problem.
A new class of GnRH analogues has reached the clinical
testing phase. These are GnRH antagonists, which im-
mediately block the GnRH receptors to access by native
GnRH peptides. Clinically the antagonists differ from the
superagonists in that the initial hyper-stimulation and
release of LH and FSH do not occur [6]. While the net re-
sult of the treatments by agonists and antagonists ap-
pears to be the same, two characteristic of the
antagonists make it essential to determine whether re-
turn to fertility may be a problem and of regulatory inter-
est. The first is the necessity for a loading dose at the
beginning (the first day or two) of a treatment regimen
and the considerably lower dose requirement thereafter
to sustain suppression. The second characteristic is the
propensity of at least some of the antagonists to be lig-
ands for extra-pituitary GnRH receptors such as those in
prostate tissue and elsewhere [7–11]. There is concern
that, whatever the mechanism might be, protracted ad-
ministration of effective antagonist doses might make a
return to fertility more difficult. The concern is height-
ened by the likelihood that antagonists will be used for
treatment of benign prostatic hypertrophy, a condition
in men who might wish at some future time to sire off-
spring.
A potent GnRH antagonist, orntide, that shares with oth-
er GnRH analogues the need for a loading dose, is being
developed in depot formulations (microspheres) for long
term administration (months-years) [12–14]. One such
formulation, a potential four month microsphere prepa-
ration in PLGA, was evaluated in male rats for its release
kinetics and effectiveness of castration [14]. This report
is an evaluation of the effect of a long term treatment
with a GnRH antagonist, orntide acetate, on the fertility
of male rats. Treated male rats which recovered from




Orntide acetate (Fig. 1A, with comparison to native
GnRH (B) and super-agonist leuprolide (C)) was sup-
plied by California Peptide Research, Inc. (Napa, CA)
and was 99% pure. The polymer for microsphere formu-
lation, 85:15 poly(D,L-lactide-co-glycolide) (PLGA) was
obtained from Birmingham Polymers, Inc. (Birming-
ham, AL). Orntide microspheres were prepared as previ-
ously described [13]. Proven breeder female Sprague
Dawley rats weighing approximately 230 g were pur-
chased from Harlan (Indianapolis, IN) and used imme-
diately after the quarantine period required by a
University of Kentucky Animal Research Facility ap-
proved protocol. Sprague Dawley male rats were those
that had been treated with a 4 month dose of orntide [14]
and allowed a sufficient period of time for wash out.
Methods
In vivo evaluation of orntide microspheres
Two groups of male Sprague Dawley rats (n = 6) were
used in this study. Group I (rats 1–6) received 120-day
orntide microspheres (8.8 mg orntide/kg) prepared with
the polymer (16% drug load) in vehicle, and animals in
Group II (rats 7–12) were used as controls and received
vehicle (1% carboxymethylcellulose and 2% mannitol
(w/v)) alone. The injections were administered subcuta-
neously with an 18G needle between the scapulae. Blood
samples were collected from the tail vein at predeter-
mined time points. The serum was separated and frozen
until analysis. The animals were challenged with 10 µg/
kg LHRH after routine sampling at days 77 and 91 and
additional samples were taken at 2 and 24 hours after the
challenges. Following the 120 day treatment period, the
orntide microsphere treated rats were subjected to a
washout period until they resumed and maintained sim-
ilar testosterone levels as the control before the fertility
assessment. A challenge dose of LHRH was adminis-
tered during the washout period at 173 days.
Serum orntide levels in rats were measured using a
radioimmunoassay1. Tyrl-orntide was radioiodinated by
the lactoperoxidase method and the labeled ligand was
purified by HPLC. Orntide was conjugated by the carbo-
diimide method and the antibody to orntide was pro-
duced in rabbits. The lower detection limit of the assay
was 0.008 ng/ml. The intra- and interassay coefficients
of variation were 6% and 9%, respectively.
Serum testosterone levels were assayed using Active™
Testosterone RIA DSL-4000 kits (Diagnostic Systems,
Inc., Webster, TX). The lower limit of detection for this
assay was 0.08 ng/ml and the intra- and interassay coef-
ficients of variation were 10 and 9%, respectively.
Fertility assessment
After orntide levels were no longer detectable as shown
in Figure 2 and the testosterone levels of the treated ani-
mals had returned to and been maintained at normal lev-
els (Figure 3), each male rat from Groups I and II was
housed in a cage with two proven breeder females. A
proven breeder female is defined as having given birth to
at least two offsprings. The study was continued until
most of the females gave birth. After completion of the
study, the baby rats were counted and separated by sex
with observation for abnormality at the time of weaning.
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Statistical evaluation of data
Drug and testosterone data are presented as means ±
standard deviation. For values below the assay detection
limit the limit was used for calculations.
Results and Discussion
Release kinetics and pharmacodynamics
Figures 2 and 3 show the release kinetics of these micro-
spheres and the resultant rapid and profound testoster-
one suppression that resulted in the treated animals.
This information confirms that the treated animals were,
indeed, rendered incapable of producing offspring dur-
ing the treatment. As shown in Figure 2 administration
of orntide microspheress initially resulted in high serum
drug levels in rats (Cmax 52 ng/mL after 6 h). Subse-
quent release resulted in a peak level of 20 ng/mL on day
8 after which orntide levels decreased to approximately
3 ng/mL and remained there for at least 60 days before
decreasing gradually to below 1 ng/mL at day 109. The
initial orntide levels may be due to the release of the frac-
tion of the peptide residing at or near the accessible sur-
faces of the polymeric matrix in this formulation. The
second elevation in the orntide release profile may be at-
tributed to a diffusion-controlled release. The remainder
of the release profile is likely a result of erosion-control-
led peptide release from the microspheres [12–14].
Figures 3 shows serum testosterone levels in groups I
and II, respectively. The immediate testosterone sup-
pression seen in group I was associated with the signifi-
cant release of GnRH antagonist from the microspheres.
Complete suppression of testosterone was observed
through 109 days and chemical castration (defined as
testosterone < 0.5 ng/ml) persisted to 145 days for four
of the orntide treated animals. Challenges at 77 and 91
days with LHRH (10 µg/kg) did not elevate the testoster-
Figure 2
Mean serum orntide levels in rats after administration of 120-day orntide ms (Group I). The insert shows initial serum orntide
levels
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one levels indicating that good suppression was main-
tained at those time points. The levels elevated above 1
ng/ml sometime between 145 days and 173 days. The re-
turn to normal was confirmed by a challenge at 173 days
which showed the same testosterone elevation as that
seen in the untreated animals at 77 and 91 days. Figure 3
showed that during the period from 173 days to 269 days,
the testosterone levels of treated and untreated were
similar, fluctuating in a manner that is typical of normal
rats.
Fertility assessment
At 269 days after the initial injections, the animals were
placed with the females to assess fertility. By this time
the animals were more than a year old, and problems
with fertility would not have been a surprise.
Table 1I shows the number of offsprings born to each of
the female rats that were housed with the designated
male rat. All of the females housed with the treated males
gave birth. A total of 123 offspring (62 male, 61 female)
average 12.3 offspring per litter (range 3–17) and 24.6
offspring per male (range 17–33). The control group was
seemingly less productive in that the females housed
with males #7 and #12, and one of those housed with #10
had no offspring. Eliminating those with no offspring,
the average number of offspring per male was 21.1 (range
10–28), similar to that from treated males, and the off-
spring per litter was 10.6 (range 3–15), also close to the
treated.
All of the offspring survived to the time of weaning and
were morphologically and behaviorally normal. Figure 4
is a photograph showing the offspring of female 2 mated
with male rat #11 (vehicle treated) and of female 2 mated
with male rat #3 (orntide microspheres treated) along
with their mothers. The dates of birth were two days
apart.
Conclusions
Adult male rats that had been rendered chemically cas-
trate for 4 months or more with orntide released from a
Figure 3
Mean serum testosterone levels in rats treated with 120-day orntide ms (Group I) and in control animals (Group II)
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depot formulation were able to return to fertility. This
suggests that this GnRH antagonist may be safely used in
patients who may wish to regain their capacity for repro-
duction after hormonal treatment.
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Table I: Number of offspring produced by orntide treated and drug-free rats
Male Rat # Female Rat # Male offspring Female offspring
Group I 1 1 5 6
Treated 2 6 4
with 2 1 3 10
Orntide MS 2 12 5
3 1 2 1
2 3 11
4 1 10 7
2 9 7
5 1 8 5
2 4 5
6* -- -- --
-- -- --
Group II 7 1 0 0
Control 2 0 0
8 1 7 6
2 7 8
9 1 3 4
2 6 7
10 1 5 5
2 0 0
11 1 2 1
2 9 4
12 1 0 0
2 0 0
* Male rat #6 died on day 192 during anesthesia
Figure 4
Left: Offspring produced by male rat #11 (control) and
female #2 Right: Offspring produced by male rat #3 (orntide
treated) and female #2.
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